Progyny (NASDAQ:PGNY) Releases FY 2025 Earnings Guidance

Progyny (NASDAQ:PGNY) issued an update on its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 1.520-1.620 for the period, compared to the consensus EPS estimate of 1.660. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Progyny also updated its Q1 2025 guidance to 0.440-0.470 EPS.

Analyst Upgrades and Downgrades

PGNY has been the topic of several research reports. Truist Financial restated a “hold” rating and set a $19.00 price objective (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Bank of America upped their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, February 11th. Barclays cut their price target on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Canaccord Genuity Group cut their target price on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. raised their price objective on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $25.83.

Progyny Stock Performance

NASDAQ PGNY opened at $22.88 on Friday. The company has a market capitalization of $1.95 billion, a PE ratio of 39.45, a price-to-earnings-growth ratio of 2.39 and a beta of 1.34. Progyny has a 52-week low of $13.39 and a 52-week high of $38.98. The company has a 50-day simple moving average of $20.52 and a 200 day simple moving average of $18.68.

Insider Activity

In other news, CEO Peter Anevski purchased 209,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were purchased at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the transaction, the chief executive officer now directly owns 441,463 shares of the company’s stock, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman David J. Schlanger acquired 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The stock was purchased at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now owns 228,269 shares in the company, valued at $3,350,988.92. The trade was a 191.65 % increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.